EUVIMEDEUVIMED entdecken
Crossref

Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors

Takahito Negishi, Hiroki Kobayashi, Nobuki Furubayashi, Kaede Morihara, Motonobu Nakamura, Takahito Negishi

Oncology · 2025

DOI: 10.1159/000543541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Takahito Negishi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan. Hauptthemen laut MEDLINE: Quality of Life, Immune Checkpoint Inhibitors, Carcinoma, Transitional Cell, Urologic Neoplasms. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Health-related quality of life (HRQOL) has been reported in clinical trials of pembrolizumab and avelumab treatment of locally advanced or metastatic urothelial carcinoma. However, few studies have investigated the effect of immune checkpoint inhibitors (ICIs) on HRQOL in patients with urothelial carcinoma in a real-world setting.

Methods

We included 44 patients with advanced urothelial cancer who were treated with pembrolizumab or avelumab from January 2018 to November 2023. When patients visited our hospital for treatment, we evaluated their HRQOL using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-Palliative Care. We retrospectively reviewed the interview sheets.

Results

The median time to deterioration in global health status was 19.1 weeks. The mean scores of emotional functioning were improved in weeks 18 and 36 compared with baseline. The mean scores for fatigue and appetite loss were also improved in weeks 18 and 36.

Conclusion

ICI treatment for advanced urothelial carcinoma did not worsen HRQOL over time in a real-world setting. Tolerability of ICIs for advanced urothelial carcinoma appears good in those who received long-term treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeImmune Checkpoint InhibitorsCarcinoma, Transitional CellUrologic NeoplasmsUrinary Bladder NeoplasmsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAntibodies, Monoclonal, HumanizedAged, 80 and over

Stichwörter der Autor:innen

Health-related quality of lifeImmune checkpoint inhibitorsUrothelial carcinoma

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanizedpembrolizumabavelumab

Autor:innen und Institutionen

  • Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan.

Zitieren

APA

Negishi, T., Kobayashi, H., Furubayashi, N., Morihara, K., Nakamura, M., & Negishi, T. (2025). Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. Oncology. https://doi.org/10.1159/000543541

Vancouver

Negishi T, Kobayashi H, Furubayashi N, Morihara K, Nakamura M, Negishi T. Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. Oncology. 2025. doi:10.1159/000543541

BibTeX
@article{Negishi2025,
  author = {Negishi, Takahito and Kobayashi, Hiroki and Furubayashi, Nobuki and Morihara, Kaede and Nakamura, Motonobu and Negishi, Takahito},
  title = {Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000543541}
}
Kostenlos starten →